BridgeBio Pharma (BBIO) said Sunday that its drug acoramidis reduced mortality and hospitalizations within the first month of treatment in patients with transthyretin amyloid cardiomyopathy.

The company said patients treated with the drug showed "numerically fewer" cumulative events compared to placebo.

The drug also reduced hazards by 49% after 30 months and by 45% after 42 months compared to a placebo, the company said.

The illness, caused by a buildup of proteins in the heart, can lead to death and hospitalization.

Acoramidis is approved as Attruby by the US Food and Drug Administration and as Beyonttra by European, Japanese, and the UK authorities for stabilization of transthyretin amyloid cardiomyopathy, the company said.